Kura Oncology announced that it has completed enrollment of 85 patients in the Phase 2 portion of KOMET-001, a registration-directed clinical trial of the Company’s menin inhibitor, ziftomenib, in patients with relapsed or refractory NPM1-mutant acute myeloid leukemia. The Company expects to report topline data from the trial in early 2025. “We are thrilled to announce this critical milestone, which brings us one step closer to delivering ziftomenib as a potentially best-in-class treatment for patients with genetically defined acute leukemias,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
- Kura Oncology to Participate in Bank of America Securities Healthcare Conference
- Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Kura Oncology reports inducement grants under Nasdaq listing rule
- Kura Oncology reports Q1 EPS (59c), consensus (55c)